[{"orgOrder":0,"company":"Earendil Labs","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"HXN-1002","moa":"Alpha-4-beta-7\/TL1A","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Earendil Labs","amount2":1.8500000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":1.8500000000000001,"dosageForm":"Undisclosed","sponsorNew":"Earendil Labs \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Earendil Labs \/ Sanofi"}]

Find Clinical Drug Pipeline Developments & Deals by Earendil Labs

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Under the licensing agreement, Sanofi will obtain exclusive worldwide rights to antibody, HXN-1002. It is designed to provide a treatment option for patients with ulcerative colitis.

                          Product Name : HXN-1002

                          Product Type : Antibody

                          Upfront Cash : $125.0 million

                          April 17, 2025

                          Lead Product(s) : HXN-1002

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Sanofi

                          Deal Size : $1,845.0 million

                          Deal Type : Licensing Agreement

                          blank